{
  "id": "who_polycythemia_vera_criteria",
  "title": "WHO Diagnostic Criteria for Polycythemia Vera (2016)",
  "description": "World Health Organization 2016 diagnostic criteria for polycythemia vera. Requires 3 major criteria OR 2 major criteria + 1 minor criterion for diagnosis. Designed to detect masked polycythemia vera cases missed by previous 2008 criteria.",
  "category": "hematology",
  "version": "2016",
  "parameters": [
    {
      "name": "gender",
      "type": "string",
      "required": true,
      "description": "Patient gender (affects hemoglobin and hematocrit thresholds)",
      "options": ["male", "female"],
      "validation": {
        "enum": ["male", "female"]
      }
    },
    {
      "name": "hemoglobin",
      "type": "float",
      "required": true,
      "description": "Hemoglobin level in g/dL",
      "validation": {
        "min": 5.0,
        "max": 25.0
      },
      "unit": "g/dL"
    },
    {
      "name": "hematocrit",
      "type": "float",
      "required": true,
      "description": "Hematocrit percentage",
      "validation": {
        "min": 10.0,
        "max": 80.0
      },
      "unit": "%"
    },
    {
      "name": "red_cell_mass_elevated",
      "type": "string",
      "required": true,
      "description": "Red cell mass >25% above mean normal predicted value (alternative to Hgb/Hct criteria)",
      "options": ["yes", "no", "not_measured"],
      "validation": {
        "enum": ["yes", "no", "not_measured"]
      }
    },
    {
      "name": "bone_marrow_hypercellular",
      "type": "string",
      "required": true,
      "description": "Bone marrow biopsy showing hypercellularity for age with trilineage growth including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes",
      "options": ["yes", "no", "not_performed"],
      "validation": {
        "enum": ["yes", "no", "not_performed"]
      }
    },
    {
      "name": "jak2_mutation",
      "type": "string",
      "required": true,
      "description": "Presence of JAK2V617F or JAK2 exon 12 mutation",
      "options": ["jak2v617f_positive", "jak2_exon12_positive", "negative", "not_tested"],
      "validation": {
        "enum": ["jak2v617f_positive", "jak2_exon12_positive", "negative", "not_tested"]
      }
    },
    {
      "name": "erythropoietin_level",
      "type": "string",
      "required": true,
      "description": "Serum erythropoietin (EPO) level status",
      "options": ["subnormal", "normal", "elevated", "not_measured"],
      "validation": {
        "enum": ["subnormal", "normal", "elevated", "not_measured"]
      }
    }
  ],
  "result": {
    "name": "diagnosis_status",
    "type": "string",
    "unit": "categorical",
    "description": "Diagnostic result based on WHO 2016 criteria"
  },
  "interpretation": {
    "categories": [
      {
        "value": "diagnosis_met",
        "description": "WHO criteria for polycythemia vera diagnosis are met",
        "interpretation": "Patient meets WHO 2016 diagnostic criteria for polycythemia vera. Diagnosis confirmed."
      },
      {
        "value": "probable_pv",
        "description": "Some criteria met but diagnosis incomplete",
        "interpretation": "Some WHO criteria met but additional testing or criteria fulfillment needed to confirm polycythemia vera diagnosis."
      },
      {
        "value": "criteria_not_met",
        "description": "WHO criteria for polycythemia vera diagnosis are not met",
        "interpretation": "Current findings do not meet WHO 2016 diagnostic criteria for polycythemia vera. Consider alternative diagnoses or additional testing."
      }
    ]
  },
  "references": [
    "Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi: 10.1182/blood-2016-03-643544",
    "Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi: 10.1038/s41408-018-0054-y",
    "Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599-1613. doi: 10.1002/ajh.26008",
    "Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786-793. doi: 10.1111/bjh.13884"
  ],
  "formula": "Diagnosis requires meeting 3 major criteria OR 2 major criteria + 1 minor criterion. Major criteria: (1) Hemoglobin >16.5 g/dL (men) or >16.0 g/dL (women) OR Hematocrit >49% (men) or >48% (women) OR elevated red cell mass >25% above normal; (2) Bone marrow hypercellularity with trilineage growth; (3) JAK2V617F or JAK2 exon 12 mutation. Minor criterion: Subnormal serum erythropoietin level.",
  "notes": [
    "The 2016 WHO criteria lowered hemoglobin thresholds from the 2008 criteria to detect masked polycythemia vera cases",
    "Hematocrit thresholds were newly introduced in 2016 as alternative to hemoglobin levels",
    "Bone marrow morphology was elevated from minor to major criterion in 2016",
    "JAK2V617F mutation is found in ~95% of PV patients; JAK2 exon 12 mutations in ~3% of cases",
    "Subnormal EPO level helps distinguish PV from secondary polycythemia",
    "These criteria are specifically for polycythemia vera and not other myeloproliferative neoplasms",
    "Bone marrow biopsy is essential for diagnosis and should show age-adjusted hypercellularity",
    "Alternative erythroid mass measurement may be used when Hgb/Hct are borderline"
  ]
}